NASDAQ:CDXS - Codexis Stock Price, Forecast & News

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis, Inc. (NASDAQ:CDXS) announced its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.10. The biotechnology company had revenue of $21.91 million for the quarter, compared to analysts' expectations of $16.56 million. Codexis had a negative net margin of 17.85% and a negative return on equity of 15.24%. View Codexis' Earnings History.

Codexis is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Codexis.

4 Wall Street analysts have issued twelve-month price objectives for Codexis' stock. Their forecasts range from $19.00 to $25.00. On average, they anticipate Codexis' share price to reach $21.63 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price. View Analyst Price Targets for Codexis.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.

Media headlines about CDXS stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Codexis earned a news impact score of 0.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the near term. View News Stories for Codexis.

Codexis saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,380,000 shares, an increase of 7.0% from the September 15th total of 5,030,000 shares. Based on an average daily trading volume, of 459,800 shares, the short-interest ratio is currently 11.7 days. Currently, 10.1% of the company's shares are sold short. View Codexis' Current Options Chain.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA), NVIDIA (NVDA), General Electric (GE), Corbus Pharmaceuticals (CRBP), Cisco Systems (CSCO), Ford Motor (F) and ImmunoGen (IMGN).

Codexis' stock is owned by many different of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (4.70%), Nikko Asset Management Americas Inc. (2.40%), Sumitomo Mitsui Trust Holdings Inc. (2.40%), State Street Corp (1.81%), Stifel Financial Corp (1.12%) and Assenagon Asset Management S.A. (0.55%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Institutional Ownership Trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Squarepoint Ops LLC, Ingalls & Snyder LLC, Barclays PLC, Strs Ohio, State Street Corp and Great West Life Assurance Co. Can. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch. View Insider Buying and Selling for Codexis.

CDXS stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Assenagon Asset Management S.A., Gilder Gagnon Howe & Co. LLC, Millennium Management LLC, SG Americas Securities LLC, State of New Jersey Common Pension Fund D and Roubaix Capital LLC. Company insiders that have bought Codexis stock in the last two years include John J Nicols and Patrick Y Yang. View Insider Buying and Selling for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $15.81.

Codexis has a market capitalization of $925.17 million and generates $60.59 million in revenue each year. The biotechnology company earns $-10,880,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.View Additional Information About Codexis.

The official website for Codexis is http://www.codexis.com/.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]